Risk stratification of ibrutinib toxicity co-administered with triazole antifungals: insights from real-world pharmacovigilance and clinical evidence
Objective The co-administration of ibrutinib and triazole antifungals results in known pharmacokinetic interactions, but the comprehensive clinical risk profile and grading characteristics remain underexplored. This study integrated real-world pharmacovigilance data, clinical pharmacokinetic studies, and published clin...